Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | FAH | CTRPv2 | pan-cancer | AAC | -0.14 | 2e-05 |
mRNA | CDH24 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
mRNA | ZFP1 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
mRNA | ZIC5 | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
mRNA | ZFPL1 | CTRPv2 | pan-cancer | AAC | -0.15 | 2e-05 |
mRNA | NEURL4 | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
mRNA | NRXN1 | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
mRNA | KDM1A | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
mRNA | LINGO1 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
mRNA | DYM | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |